International Journal of Pharmaceutical Compounding

A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

LEARN MORE

PreScription: Comments on the FDA Guidance "Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry"

Author(s): Allen Loyd V Jr

Issue: Mar/Apr 2022 - Volume 26, Number 2
View All Articles in Issue

Page(s): 92

PreScription: Comments on the FDA Guidance

Download in electronic PDF format for $75

Abstract:

Related Keywords: Loyd V. Allen, Jr., PhD, RPh, U.S. Food and Drug Administration, FDA, Code of Federal Regulations, FDA Guidance for Industry, Federal Food, Drug, and Cosmetic Act section 503A, drug product, pharmaceutical equivalence, pharmaceutical alternatives, finished dosage form

Related Categories: LEGAL, DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A Blankenship Cynthia E	Sep/Oct 2014 Pg. 379-380
PreScription: Comments on the FDA Guidance "Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry" Allen Loyd V Jr	Mar/Apr 2022 Pg. 92
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Cabaleiro Joe	Sep/Oct 2021 Pg. 358-362
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
Allowing Compounding Pharmacies to Address Drug Shortages Broughel James	Mar/Apr 2022 Pg. 100-109
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh Allen Loyd V Jr	Nov/Dec 2003 Pg. 449-450
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing Allen Loyd V Jr	Mar/Apr 2018 Pg. 92
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)	Nov/Dec 2016 Pg. 457-458
Standing Together Fixing the Drug Quality and Security Act Miller David G	Mar/Apr 2015 Pg. 104-106
Compounding OTC Drugs: A Legal Perspective Gibbs Jeffrey N, Mazan Kate Duffy	May/Jun 2000 Pg. 180-181
Drugs Banned for Use in Food Animals: An Explanation Davidson Gigi S	Mar/Apr 2001 Pg. 101-103
PostScription: Drug Disposal: Compounding Pharmacists' Involvement in the Prevention of Prescription Drug Misuse and Abuse Williams LaVonn A	Nov/Dec 2011 Pg. 526-527
Drug Shortages & Discontinued Drugs: The Effects on Patients and Healthcare Providers Allen Loyd V Jr, Williams LaVonn A	Jul/Aug 2012 Pg. 294-298
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug	Mar/Apr 2017 Pg. 95-102
International Academy of Compounding Pharmacists' Legislative Regulatory Update: Take Action! Stop the U.S. Good and Drug Administration's Misguided Veterminary Guidance Miller David G	Nov/Dec 2015 Pg. 449-450
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr	Sep/Oct 2015 Pg. 389-390
PreScription: Discontinued Drugs and Drug Shortages Allen Loyd V Jr	Mar/Apr 2011 Pg. 92
Return to Top